This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MacKeigan, J. P. Articles by Ting, J. P-Y. Search for Related Content PubMed PubMed Citation Articles by MacKeigan, J. P. Articles by Ting, J. P-Y.

Inactivation of the Antiapoptotic Phosphatidylinositol 3-Kinase-Akt Pathway by the Combined Treatment of Taxol and Mitogen-activated Protein Kinase Kinase Inhibition¹

Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology [J. P. M., D. J. T., J. P-Y. T.], Department of Pharmacology [D. H., H. S. E., L. M. G.], University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599

Paclitaxel (Taxol) activates a number of signal transduction pathways that lead to apoptosis.In contrast, paclitaxel also activates cell survival pathways, such as the Raf-mitogen-activated protein kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway. Previously, we have shown that inhibition of MEK combined with paclitaxel treatment causes an impressive enhancement of apoptosis in various tumor cell lines. Here, we find that the combination of paclitaxel with a MEK inhibitor leads to a dramatic inactivation of the antiapoptotic Akt (protein kinase B) kinase. The decrease in Akt is not reflected at the protein or mRNA level but rather attributed to kinase inactivation. To confirm that inactivation of Akt is significant, a constitutively active Akt mutant was introduced and shown to reverse tumor cell apoptosis. Further analysis upstream of Akt shows that treatment with the combination of paclitaxel and MEK inhibitor down-regulates PI3K activity more than either agent alone. The direct pharmacological inhibition of phosphatidylinositol 3-kinase (PI3K) similarly enhances paclitaxel-induced tumor apoptosis in a dose-dependent manner. Our results suggest the combination of paclitaxel and MEK inhibitor leads to down-regulation of the PI3K-Akt signaling in addition to the proapoptotic effects of paclitaxel and MEK inhibitor alone. Overall, these findings render the combined use of paclitaxel with MEK inhibitors, or paclitaxel with PI3K inhibitors, as a promising new strategy for cancer chemotherapy.

This article has been cited by other articles:

				C. Sourbier, S. Danilin, V. Lindner, J. Steger, S. Rothhut, N. Meyer, D. Jacqmin, J.-J. Helwig, H. Lang, and T. Massfelder Targeting the Nuclear Factor-{kappa}B Rescue Pathway Has Promising Future in Human Renal Cell Carcinoma Therapy Cancer Res., December 15, 2007; 67(24): 11668 - 11676. [Abstract] [Full Text] [PDF]

				B. R. Davies, A. Logie, J. S. McKay, P. Martin, S. Steele, R. Jenkins, M. Cockerill, S. Cartlidge, and P. D. Smith AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models Mol. Cancer Ther., August 1, 2007; 6(8): 2209 - 2219. [Abstract] [Full Text] [PDF]

				M. S. Choe, Z. Chen, C. M. Klass, X. Zhang, and D. M. Shin Enhancement of Docetaxel-Induced Cytotoxicity by Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 Pathways in Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., May 15, 2007; 13(10): 3015 - 3023. [Abstract] [Full Text] [PDF]

				C. Sourbier, V. Lindner, H. Lang, A. Agouni, E. Schordan, S. Danilin, S. Rothhut, D. Jacqmin, J.-J. Helwig, and T. Massfelder The Phosphoinositide 3-Kinase/Akt Pathway: A New Target in Human Renal Cell Carcinoma Therapy. Cancer Res., May 15, 2006; 66(10): 5130 - 5142. [Abstract] [Full Text] [PDF]

				A. Sunters, P. A. Madureira, K. M. Pomeranz, M. Aubert, J. J. Brosens, S. J. Cook, B. M.T. Burgering, R. C. Coombes, and E. W.-F. Lam Paclitaxel-Induced Nuclear Translocation of FOXO3a in Breast Cancer Cells Is Mediated by c-Jun NH2-Terminal Kinase and Akt Cancer Res., January 1, 2006; 66(1): 212 - 220. [Abstract] [Full Text] [PDF]

				K. Zhu, E. Gerbino, D. M. Beaupre, P. A. Mackley, C. Muro-Cacho, C. Beam, A. D. Hamilton, M. G. Lichtenheld, W. G. Kerr, W. Dalton, et al. Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells Blood, June 15, 2005; 105(12): 4759 - 4766. [Abstract] [Full Text] [PDF]

				H. M. McDaid, L. Lopez-Barcons, A. Grossman, M. Lia, S. Keller, R. Perez-Soler, and S. Band Horwitz Enhancement of the Therapeutic Efficacy of Taxol by the Mitogen-Activated Protein Kinase Kinase Inhibitor CI-1040 in Nude Mice Bearing Human Heterotransplants Cancer Res., April 1, 2005; 65(7): 2854 - 2860. [Abstract] [Full Text] [PDF]

				K. Jiang, J. Sun, J. Cheng, J. Y. Djeu, S. Wei, and S. Sebti Akt Mediates Ras Downregulation of RhoB, a Suppressor of Transformation, Invasion, and Metastasis Mol. Cell. Biol., June 15, 2004; 24(12): 5565 - 5576. [Abstract] [Full Text] [PDF]

				H. W. Cheung, M.-t. Ling, S. W. Tsao, Y.C. Wong, and X. Wang Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells Carcinogenesis, June 1, 2004; 25(6): 881 - 887. [Abstract] [Full Text] [PDF]

				E. Arimoto-Ishida, M. Ohmichi, S. Mabuchi, T. Takahashi, C. Ohshima, J. Hayakawa, A. Kimura, K. Takahashi, Y. Nishio, M. Sakata, et al. Inhibition of Phosphorylation of a Forkhead Transcription Factor Sensitizes Human Ovarian Cancer Cells to Cisplatin Endocrinology, April 1, 2004; 145(4): 2014 - 2022. [Abstract] [Full Text] [PDF]

				S. Pervin, R. Singh, W. A. Freije, and G. Chaudhuri MKP-1-Induced Dephosphorylation of Extracellular Signal-Regulated Kinase Is Essential for Triggering Nitric Oxide-Induced Apoptosis in Human Breast Cancer Cell Lines: Implications in Breast Cancer Cancer Res., December 15, 2003; 63(24): 8853 - 8860. [Abstract] [Full Text] [PDF]

				D. J. Taxman, J. P. MacKeigan, C. Clements, D. T. Bergstralh, and J. P-Y. Ting Transcriptional Profiling of Targets for Combination Therapy of Lung Carcinoma with Paclitaxel and Mitogen-activated Protein/Extracellular Signal-regulated Kinase Kinase Inhibitor Cancer Res., August 15, 2003; 63(16): 5095 - 5104. [Abstract] [Full Text] [PDF]

				Y. Hu, M. Bally, W. H. Dragowska, and L. Mayer Inhibition of Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase Kinase Enhances Chemotherapeutic Effects on H460 Human Non-Small Cell Lung Cancer Cells through Activation of Apoptosis Mol. Cancer Ther., July 1, 2003; 2(7): 641 - 649. [Abstract] [Full Text] [PDF]

				K. Shimada, M. Nakamura, E. Ishida, M. Kishi, and N. Konishi Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis Carcinogenesis, June 1, 2003; 24(6): 1067 - 1075. [Abstract] [Full Text] [PDF]

				J. Asakuma, M. Sumitomo, T. Asano, T. Asano, and M. Hayakawa Selective Akt Inactivation and Tumor Necrosis Factor-related Apoptosis-inducing Ligand Sensitization of Renal Cancer Cells by Low Concentrations of Paclitaxel Cancer Res., March 15, 2003; 63(6): 1365 - 1370. [Abstract] [Full Text] [PDF]